1. Can the level of CD52 expression on Sézary cells be used to predict the response of Sézary syndrome to alemtuzumab? 
Iolanda Conde Fernandes, MD, Marta Gonçalves, BS, Maria dos Anjos Teixeira, MD, Cristina Gonçalves, MD, Jorge Coutinho, MD, Manuela Selores, MD, Rosário Alves, MD, Margarida Lima, PhD 
Journal of the American Academy of Dermatology 
Volume 67, Issue 5, Pages (November 2012)
DOI: /j.jaad
Copyright © 2012 American Academy of Dermatology, Inc. Terms and Conditions

2. Fig 1
Representative flow cytometry dot plots and histograms illustrating expression of CD52 on different leukocyte populations of 2 patients with Sézary syndrome, one of them (patient 4) responsive (A) and another (patient 6) refractive (B) to alemtuzumab. Note that neoplastic CD4+ T cells (blue dots) from patient refractive to anti-CD52 therapy are selectively deficient on CD52.
Journal of the American Academy of Dermatology  , DOI: ( /j.jaad )
Copyright © 2012 American Academy of Dermatology, Inc. Terms and Conditions